Opinion|Videos|January 31, 2025
Sarah’s Journey Through CAR-T Therapy: Pre-, Peri-, and Post-Treatment Considerations with Ide-cel
This video episode examines decision-making between CAR-T therapy and novel agents in the second-line setting, scenarios for preferring alternative therapies, and treatment strategies following progression after ide-cel, emphasizing the impact of prior CAR-T therapy on subsequent choices.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do you approach the decision between CAR-T therapy and other novel agents in the second-line setting?
- In which scenarios might you prefer alternative therapies over CAR-T?
- If Sarah were to progress after ide-cel therapy, what would be your next steps?
- How does prior CAR-T therapy influence subsequent treatment choices?
Advertisement
Related to this article
William A. Hall, MD, discussed how preoperative SBRT may serve as a platform for novel systemic therapies in pancreatic adenocarcinoma.
At 8 years, SBRT and radical prostatectomy had similar disease control in the PACE-A trial, with less urinary incontinence after SBRT.
Chih-Yi “Andy” Liao, MD, discusses early clinical data for KRAS G12C and G12D inhibitors in cholangiocarcinoma, noting that trials are just getting started.
“When we give the most effective therapy at the time of new diagnosis, we get the most value out of the effort and time that we and our patients are spending,” said Neeraj Agarwal, MD, FASCO.
An aglatimagene besadenovec-based radiotherapy combination increased intratumoral lymphocyte fraction in intermediate- to high-risk localized prostate cancer.
The ROADS investigators reported no differences between cesium-131 tile-based radiation therapy and SRT in quality of life, functional status, or neurocognitive function.
William A. Hall, MD, discussed the SOFT Preop study of preoperative SBRT vs conventional chemoradiation for pancreatic adenocarcinoma.
Chih-Yi “Andy” Liao, MD, discusses how oncologists are sequencing pemigatinib, futibatinib, and lirafugratinib and how their tolerability differs.
Advertisement
Advertisement
Trending on CancerNetwork
1
Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer
2
What Does TALAPRO-3 Mean for Frontline Treatment of HRR-Altered mHSPC?
3
SBRT Matches Chemoradiation, Preserves QOL Before Pancreatic Surgery
4
Tile-Based Radiation Improves Surgical Bed Recurrence in Brain Metastases
5